Hikma completes Xellia acquisition
Hikma has completed its acquisition of Xellia Pharmaceuticals’ U.S. finished dosage form business and related assets following clearance under applicable U.S. antitrust laws. The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities and an R&D center in Zagreb, Croatia.
Hikma has paid cash consideration of $135 million (subject to customary adjustments), with additional contingent consideration of up to $50 million payable upon achievement of certain regulatory and commercial milestones.
[Read more: Hikma intros Kloxxado]
Transaction highlights:
- Supports the long-term growth of Hikma’s Injectables business
- Diversifies and enriches Hikma’s U.S. injectables portfolio and pipeline
- Expands Hikma’s high-quality manufacturing capacity
- Adds complex manufacturing technologies
- Enhances Hikma’s R&D capabilities
Bill Larkins, president of Injectables, said, “This acquisition adds significant scale to our U.S. operations and enhances our U.S. injectable manufacturing capabilities and portfolio by adding complex technologies. I am confident that this transaction will deliver significant future value to our Injectables business, supporting growth over the medium term.”
[Read more: Hikma enters Spanish generic injectables market]